A real-world study of alemtuzumab in a cohort of Italian patients.
Cinzia Valeria RussoFrancesco SaccàJessica FrauPietro AnnovazziElisabetta SignorielloSimona BonavitaRoberta GrassoMarinella ClericoCinzia CordioliAlice LaroniMarco Alfonso CapobiancoValentina Torri ClericiArianna SartoriPaola CavallaGiorgia Teresa ManiscalcoSara La GioiaFrancesca CaleriAlessia GiugnoRosa IodiceAntonio CarotenutoEleonora CoccoGiuseppe FenuMauro ZaffaroniDamiano BaronciniGiacomo LusAntonio GalloStefania Federica De MercantiCaterina LapucciValeria Di FrancescantonioLaura BrambillaMaria Pia SormaniAlessio SignoriPublished in: European journal of neurology (2021)
Alemtuzumab decreases ARR independent of previous therapy, including patients with disease activity during natalizumab treatment. Overall, 90% of patients showed no disease progression, and 20% an improvement after 2 years of alemtuzumab.
Keyphrases
- end stage renal disease
- disease activity
- ejection fraction
- chronic kidney disease
- newly diagnosed
- rheumatoid arthritis
- systemic lupus erythematosus
- multiple sclerosis
- peritoneal dialysis
- rheumatoid arthritis patients
- mesenchymal stem cells
- patient reported outcomes
- bone marrow
- juvenile idiopathic arthritis
- cell therapy
- patient reported